Intellia Therapeutics announced that it has commenced an underwritten public offering of $250M of shares of its common stock. Goldman Sachs & Co. is acting as the sole underwriter for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NTLA:
- Here’s Why Intellia (NASDAQ:NTLA) Stock Is Trending Lower
- Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
- Intellia Therapeutics Announces Proposed Public Offering of Common Stock
- Intellia Therapeutics to participate in a conference call with JPMorgan
- Intellia Therapeutics price target raised to $129 from $121 at Chardan